Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.
Info & Links
CEO
Jon Congleton
Headquarters
150 N. RADNOR CHESTER ROAD, SUITE F200 RADNOR, PA 19087, UNITED STATES
Mineralys Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
864.80M
Enterprise Value
750.71M
Enterprise Value/EBITDA(ttm)
-3.90
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
2.48
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-67.97%
Return on Invested Capital(ttm)
-73.11%
Return on Assets(ttm)
-62.40%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-192.36M
Net Income Available to Common(ttm)
-177.81M
Diluted EPS(ttm)
-3.64
Share Statistics
Beta (5Y Monthly)
1.44
52-Week Change
24.04%
S&P 500 52-Week Change
5.43%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
49.84M
Dividend Yield
0.00%
Float4
33.27M
% Held by Insiders
33.24%
% Held by Institutions
84.46%
Balance Sheet
Total Cash(mrq)
198.19M
Total Cash Per Share(mrq)
3.98
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
14.02%
Quick Ratio(mrq)
14.02%
Book Value Per Share(mrq)
3.84
Cash Flow
Operating Cash Flow Per Share(ytd)
-3.43
Free Cash Flow(ytd)
-166.41M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.